TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTC: TOBAF)
(FRANKFURT: 2TP2) (the “Company” or “Taat”) is pleased to
announce that after finalizing the base material formulation for
Beyond Tobacco™, the first production-scale batch of base material
has been shipped to the Company’s manufacturing facility to produce
an inventory of commercial samples for Beyond Tobacco™, which are
to be given to distribution, wholesale, and strategic partners. The
formulation of Beyond Tobacco™ is distinctly characterized by a
proprietary refinement method (for which the Company has recently
filed a United States patent application, as announced in its
September 4, 2020 press release) that causes the material to emit
the scent and taste of tobacco when ignited. With a planned U.S.
launch in Q4 2020, Beyond Tobacco™ is a combustible product
designed to closely emulate the experience of smoking a tobacco
cigarette. With the Beyond Tobacco™ base material formulation
officially finalized, the Company has commenced this production run
with the objective of providing Beyond Tobacco™ samples to
prospective distributors and wholesalers as part of the Company’s
current and future efforts to cultivate a strong early-stage retail
market presence in the United States.
As of 2020, there are approximately 1.3 billion tobacco users
worldwide1, many of whom seek to leave nicotine behind. In the
United States, 2018 data from the CDC indicates that 55.1% of adult
smokers had attempted to quit in the past year, though only 7.5%
successfully quit smoking in that timeframe2. The Company’s
flagship Beyond Tobacco™ product contains no tobacco or nicotine,
and it anticipates current tobacco smokers could find the
combustible “stick” format to be familiar and comparable to the
ritual of smoking a tobacco cigarette. The user experience of
Beyond Tobacco™ has been meticulously engineered to closely emulate
the sensory elements of smoking legacy tobacco products, to include
the scent and taste of tobacco, cigarette-style packaging, and
audible crackling as the product burns. Operated under the
executive leadership of ‘Big Tobacco’ veterans in strategy and
commercialization, Taat seeks to capture market share in the
tobacco industry by launching Beyond Tobacco™ in “Original” and
“Menthol” varieties. After obtaining commercial-scale manufacturing
capacity, filing a patent application for the Beyond Tobacco™ base
material refinement process, and retaining a full-service investor
relations and digital media agency in British Columbia, the Company
continues to diligently handle all groundwork that precedes the
launch of Beyond Tobacco™.
Because prospective distribution and wholesale partners will
generally request client-ready samples of any new product,
procuring commercial samples of Beyond Tobacco™ is an important
step in carrying out negotiations with such partners. After
finalizing the base material formulation for a launch-ready
iteration of Beyond Tobacco™, the Company is pursuing expeditious
production of these samples to maximize lead times in obtaining
retail presence before or during the planned Q4 2020 product
launch. A production-scale batch of the Beyond Tobacco™ base
material, which is processed privately by the Company, has been
sent to its manufacturing partner (whose name cannot be published
under the terms of its agreement with the Company), which operates
a commercial-scale manufacturing facility where it also carries out
production for national and regional tobacco cigarette brands at a
rate of up to one million sticks per minute. Once the commercial
samples of Beyond Tobacco™ have been made, the manufacturing
partner will warehouse the samples, dispatching outbound shipments
as directed by Taat.
Taat CEO Setti Coscarella commented, “Getting the flavour in the
base material just right is fundamental to the perception of Beyond
Tobacco™, when it comes to making it an attractive product for
current tobacco smokers. Because our product does not contain any
nicotine or tobacco, the value proposition of offering a
combustible product that is experientially similar to a tobacco
cigarette relies almost completely on delivering a flavour and a
scent that closely resembles actual tobacco. In the past few
months, the Company has made considerable progress in attaining
this similarity, which prompted our recent patent application
filing for the refinement process. Using the samples of Beyond
Tobacco™ that are to be made with the base material that is
currently en route to our manufacturing facility, we plan to
approach several leading distributors and wholesalers of tobacco
products to build a robust presence of Beyond Tobacco™ in the U.S.
retail market. With that market being our initial focus, I am proud
to say that every component of Beyond Tobacco™ is American-grown
and American-made. To date, we have received many requests for
samples of Beyond Tobacco™, and I am excited to be able to provide
them to our prospective partners as we get closer to our product
launch.”
Sources
1 - https://www.who.int/news-room/fact-sheets/detail/tobacco
2 -
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html
On behalf of the Board of Directors of the Company,
TAAT LIFESTYLE & WELLNESS LTD.
“Setti Coscarella”
Setti Coscarella, CEO
For further information, please contact:
Jamie Frawley1-833-TAAT-USA
(1-833-822-8872)investor@taatusa.com
About Taat Lifestyle & Wellness Ltd.
Having developed Beyond Tobacco™, which contains no tobacco or
nicotine, Taat’s objective is to introduce an innovative,
experience-driven alternative to tobacco cigarettes for tobacco
smokers who aspire to leave nicotine behind. Beyond Tobacco™, which
is to be offered in “Original” and “Menthol” varieties, is designed
to closely emulate every aspect of smoking a traditional cigarette.
From the cigarette-style packaging and stick format, to the
proprietary flavouring blend which imparts the flavour and scent of
tobacco, to the draw sensation, and the amount of smoke exhaled,
Beyond Tobacco™ has been meticulously engineered to enable smokers
to continue enjoying the ritual of smoking, while discontinuing
nicotine intake. Taat plans to launch Beyond Tobacco™ in Q4 2020
and is seeking to position itself in the USD $814 billion (2018)1
global tobacco industry to capitalize on the growing worldwide
demand for alternatives to traditional cigarettes.
For more information, please visit http://taatusa.com.
References
1 British American Tobacco - The Global Market
Forward Looking Statements
This news release contains “forward-looking information” within
the meaning of applicable Canadian securities legislation. Often,
but not always, forward-looking information and information can be
identified by the use of words such as “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur, or be
achieved. Forward-looking information in this news release includes
statements regarding the potential launch of Beyond Tobacco™, in
addition to the following: Completion of Beyond Tobacco™ sample
production, potential outcomes relating to the provision of such
samples to prospective distributor and wholesale partners. The
forward-looking information reflects management’s current
expectations based on information currently available and are
subject to a number of risks and uncertainties that may cause
outcomes to differ materially from those discussed in the
forward-looking information. Although the Company believes that the
assumptions and factors used in preparing the forward-looking
information are reasonable, undue reliance should not be placed on
such information and no assurance can be given that such events
will occur in the disclosed timeframes or at all. Factors that
could cause actual results or events to differ materially from
current expectations include: (i) adverse market conditions; (ii)
changes to the growth and size of the tobacco markets; and (iii)
other factors beyond the control of the Company. The Company
operates in a rapidly evolving environment. New risk factors emerge
from time to time, and it is impossible for the Company’s
management to predict all risk factors, nor can the Company assess
the impact of all factors on Company’s business or the extent to
which any factor, or combination of factors, may cause actual
results to differ from those contained in any forward-looking
information. The forward-looking information included in this news
release are made as of the date of this news release and the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking information whether as a result of
new information, future events or otherwise, except as required by
applicable law.
The statements in this news release have not been evaluated by
Health Canada or the U.S. Food and Drug Administration. As each
individual is different, the benefits, if any, of taking the
Company’s products will vary from person to person. No claims or
guarantees can be made as to the effects of the Company’s products
on an individual’s health and well-being. The Company’s products
are not intended to diagnose, treat, cure, or prevent any
disease.
This news release may contain trademarked names of third-party
entities (or their respective offerings with trademarked names)
typically in reference to (i) relationships had by the Company with
such third-party entities as referred to in this release and/or
(ii) client/vendor/service provider parties whose relationship with
the Company is/are referred to in this release. All rights to such
trademarks are reserved by their respective owners or
licensees.
Statement Regarding Third-Party Investor Relations
Firms
Disclosures relating to investor relations firms retained by
Taat Lifestyle & Wellness Ltd. can be found under the Company's
profile on http://sedar.com.
TAAT Global Alternatives (CSE:TAAT)
Historical Stock Chart
From Jan 2025 to Feb 2025
TAAT Global Alternatives (CSE:TAAT)
Historical Stock Chart
From Feb 2024 to Feb 2025